Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A

Next Previous
Trial Profile

Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 137173A (Primary)
  • Indications Herpes zoster
  • Focus Registrational; Therapeutic Use
  • Acronyms ZOE-HSCT; ZOSTER-002
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 14 Oct 2025 According to a GlaxoSmithKline media release, China's CHMP has approved Shingrix for prevention of shingles in adults aged 18 and over and are at increased risk due to immunodeficiency or immunosuppression. This approval is informed by 6 clinical trials (5 of which are NCT01610414, NCT01798056, NCT01767467, NCT00920218, NCT01165203) and adds to existing indication in adults aged 50 and over, making Shingrix the first and only vaccine approved for this population in China.
  • 28 Jun 2022 According to a GlaxoSmithKline media release, based on data from six clinical trials (NCT01610414, NCT01798056, NCT01767467, NCT00920218, NCT01165203), the company has submitted regulatory application to the Japanese MHLW for Shingrix for the prevention of shingles in adults aged 18 years and older who are at increased risk. This includes individuals with immunodeficiency or immunosuppression caused by known disease or therapy.
  • 25 Oct 2020 Results assessing vaccine efficacy (VE) of the adjuvanted recombinant zoster vaccine from NCT01165177, NCT01165229 and NCT01610414 presented at the IDWeek 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top